| A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer | | |
| Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy | Journal of Pharmaceutical Health Care and Sciences | 2022 |
| New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. | Journal of Oncology Pharmacy Practice | 2022 |
| Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes | Drugs and Aging | 2021 |
| Certified nurse specialists in cancer nursing and prophylactic antiemetic prescription for chemotherapy patients. | Supportive Care in Cancer | 2022 |
| Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data. | Pharmacogenomics Journal | 2022 |
| Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment | Scientific Reports | 2021 |
| A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies | Supportive Care in Cancer | 2021 |
| Chemotherapy and Prostate Cancer | | 2021 |
| 5HT RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer | Cancer Science | 2021 |
| Kanser Hastalarında Görülen Bulantı ve Kusma Semptomlarının Yönetimi | Nevşehir Bilim Ve Teknoloji Dergisi | |
| Chemotherapy Induced Nausea and Vomiting | | 2019 |
| Gastrointestinal Complications | | 2019 |
| Evaluation of Antiemetic Therapy for Breakthrough Nausea and Vomiting in Patients with Hematopoietic Stem Cell Transplantation | Korean Journal of Clinical Pharmacy | 2018 |
| A Pharmaco-Cybernetics Approach to Patient Safety | | 2017 |
| Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting | | 2016 |
| A Pharmaco-Cybernetics Approach to Patient Safety | | 2016 |
| Introduction | | 2016 |
| Clinical Management of CINV | | 2016 |
| Delayed Nausea/Emesis | | 2016 |
| Nausea and Vomiting | Pediatric Oncology | 2015 |
| A Pharmaco-Cybernetics Approach to Patient Safety | Advances in Healthcare Information Systems and Administration Book Series | 2014 |
| Palliative Care for Cancer Patients and their Families | | |
| Management of Chemotherapy Induced Nausea and Vomiting | Korean Journal of Medicine | 2012 |
| [Experience with aprepitant in the prevention of nausea and vomiting caused by highly emetic chemotherapy of lung cancer] | | 2008 |
| [Treatment of tumor therapy-induced nausea and vomiting] | | 2009 |
| Guideline-Recommended Symptom Management Strategies That Cross Over Two or More Cancer Symptoms | Oncology Nursing Forum | 2020 |
| Intergenerational comparison of 5-HTRA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database | Supportive Care in Cancer | 2021 |
| A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers | Cancer Chemotherapy and Pharmacology | 2021 |
| Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer | Expert Review of Anticancer Therapy | 2021 |
| Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis | Future Oncology | 2021 |
| Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration | Transplantation and Cellular Therapy | 2021 |
| Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials | BMC Cancer | 2021 |
| Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron | Drug Design, Development and Therapy | 2021 |
| Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database | Cancer Reports | 2021 |
| Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis | European Journal of Clinical Pharmacology | 2021 |
| Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer | Gastric Cancer | 2021 |
| Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial | JAMA Network Open | 2021 |
| Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study | Supportive Care in Cancer | 2021 |
| Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients | Drugs and Aging | 2021 |
| The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer | International Journal of Clinical Oncology | 2021 |
| Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide | Cancer Management and Research | 2021 |
| Glycemic Control as an Early Prognostic Marker in Advanced Pancreatic Cancer | Frontiers in Oncology | 2021 |
| Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis | Supportive Care in Cancer | 2021 |
| Efficacy of intravenous NEPA, a fixed NK/5-HT receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies | Critical Reviews in Oncology/Hematology | 2021 |
| A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation | Supportive Care in Cancer | 2021 |
| Pharmacists' Role in Managing Patients with Chronic Lymphocytic Leukemia | Pharmacy (Basel, Switzerland) | 2020 |
| Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review | Frontiers in Pharmacology | 2020 |
| Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective | Frontiers in Oncology | 2020 |
| Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events | International Journal of Gynecological Cancer | 2020 |
